Moreover, pharmacological inhibition of H3K9me2 deposition significantly reduced tumor-initiating activity in patient-derived CRC stem cells, emphasizing the importance of G9a as a therapeutic target to suppress CSC activity [22]. The gene discussed is EHMT2; the disease is neoplasm.